Autoimmune polyendocrine syndrome screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(16 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Autoimmune polyendocrine syndrome}}
{{Autoimmune polyendocrine syndrome}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}}{{Akshun}}
 
{{PleaseHelp}}


==Overview==
==Overview==
[[Screening]] is an important aspect in early [[diagnosis]] and management of autoimmune polyendocrine syndrome (APS). The onset of APS is often with a single [[endocrine disorder]] and the subsequent involvement of other [[endocrine]]/non-[[endocrine]] [[organs]] may take up to years or decades. In patients of APS, high [[clinical]] suspicion should be maintained for presence of other [[autoimmune disorders]]. Once a patient has been diagnosed with a single [[autoimmune]] [[endocrine disorder]], [[Screening (medicine)|screening]] should be done for presence of other [[Autoantibodies|auto-antibodies]] such as [[21-Hydroxylase|21- hydroxylase]] or 17-hydroxylase.


==Screening==
==Screening==
[[Screening]] is an important aspect in early [[diagnosis]] and management of autoimmune polyendocrine syndrome (APS). The onset of APS is often with a single [[endocrine disorder]] and the subsequent involvement of other [[endocrine]]/non-[[endocrine]] [[organs]] may take up to years or decades. In patients of APS, high [[clinical]] suspicion should be maintained for presence of other [[autoimmune disorders]]:<ref name="pmid19858318">{{cite journal |vauthors=Erichsen MM, Løvås K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, Fougner KJ, Berg TJ, Bollerslev J, Mella B, Carlson JA, Erlich H, Husebye ES |title=Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry |journal=J. Clin. Endocrinol. Metab. |volume=94 |issue=12 |pages=4882–90 |year=2009 |pmid=19858318 |doi=10.1210/jc.2009-1368 |url=}}</ref><ref name="pmid21164269">{{cite journal |vauthors=Betterle C, Morlin L |title=Autoimmune Addison's disease |journal=Endocr Dev |volume=20 |issue= |pages=161–72 |year=2011 |pmid=21164269 |doi=10.1159/000321239 |url=}}</ref><ref name="pmid15141045">{{cite journal |vauthors=Eisenbarth GS, Gottlieb PA |title=Autoimmune polyendocrine syndromes |journal=N. Engl. J. Med. |volume=350 |issue=20 |pages=2068–79 |year=2004 |pmid=15141045 |doi=10.1056/NEJMra030158 |url=}}</ref><ref name="pmid7608264">{{cite journal |vauthors=Badenhoop K, Walfish PG, Rau H, Fischer S, Nicolay A, Bogner U, Schleusener H, Usadel KH |title=Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease |journal=J. Clin. Endocrinol. Metab. |volume=80 |issue=7 |pages=2112–7 |year=1995 |pmid=7608264 |doi=10.1210/jcem.80.7.7608264 |url=}}</ref><ref name="pmid8805992">{{cite journal |vauthors=Corazza GR, Di Sario A, Cecchetti L, Jorizzo RA, Di Stefano M, Minguzzi L, Brusco G, Bernardi M, Gasbarrini G |title=Influence of pattern of clinical presentation and of gluten-free diet on bone mass and metabolism in adult coeliac disease |journal=Bone |volume=18 |issue=6 |pages=525–30 |year=1996 |pmid=8805992 |doi= |url=}}</ref><ref name="pmid10969260">{{cite journal |vauthors=Hoffenberg EJ, Bao F, Eisenbarth GS, Uhlhorn C, Haas JE, Sokol RJ, Rewers M |title=Transglutaminase antibodies in children with a genetic risk for celiac disease |journal=J. Pediatr. |volume=137 |issue=3 |pages=356–60 |year=2000 |pmid=10969260 |doi=10.1067/mpd.2000.107582 |url=}}</ref>
* In APS type 1, the time interval between onset of [[mucocutaneous]] [[candidiasis]] and [[hypoparathyroidism]] may take upto five years and further involvement of [[adrenal glands]] may take upto ten years. Thus, a high degree of [[clinical]] suspicion is necessary in [[patients]] with a single [[autoimmune]] [[endocrine disorder]].
*Once a patient has been diagnosed with a single [[autoimmune]] [[endocrine disorder]], [[Screening (medicine)|screening]] should be done for presence of other [[Autoantibodies|auto-antibodies]] such as [[21-Hydroxylase|21- hydroxylase]], [[17 alpha-hydroxylase deficiency|17-hydroxylase]], [[thyroid peroxidase]], [[parietal cell]], anti-intrinsic factor and [[islet cell]] [[antibodies]].
*Recent research has shown that in APS, [[autoantibodies]] can develop at any age and there is insufficient evidence to suggest optimum interval between testing. For example patients of [[celiac disease]] are often [[asymptomatic]] and are detected only after screening for [[transglutaminase]] [[autoantibodies]]. Thus, individuals with single [[autoimmune disorder]] should be rescreened for [[autoantibodies]] for other [[autoimmune]] conditions at appropriate intervals even if their initial [[autoantibody]] tests are negative.


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category:Disease]]
{{WH}}
[[Category:Endocrinology]]
{{WS}}
[[Category:Endocrinology]]
[[Category:Needs content]]
 
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 21:14, 27 October 2017

Autoimmune polyendocrine syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune polyendocrine syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune polyendocrine syndrome screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune polyendocrine syndrome screening

CDC on Autoimmune polyendocrine syndrome screening

Autoimmune polyendocrine syndrome screening in the news

Blogs on Autoimmune polyendocrine syndrome screening

Directions to Hospitals Treating Autoimmune polyendocrine syndrome

Risk calculators and risk factors for Autoimmune polyendocrine syndrome screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Screening is an important aspect in early diagnosis and management of autoimmune polyendocrine syndrome (APS). The onset of APS is often with a single endocrine disorder and the subsequent involvement of other endocrine/non-endocrine organs may take up to years or decades. In patients of APS, high clinical suspicion should be maintained for presence of other autoimmune disorders. Once a patient has been diagnosed with a single autoimmune endocrine disorder, screening should be done for presence of other auto-antibodies such as 21- hydroxylase or 17-hydroxylase.

Screening

Screening is an important aspect in early diagnosis and management of autoimmune polyendocrine syndrome (APS). The onset of APS is often with a single endocrine disorder and the subsequent involvement of other endocrine/non-endocrine organs may take up to years or decades. In patients of APS, high clinical suspicion should be maintained for presence of other autoimmune disorders:[1][2][3][4][5][6]

References

  1. Erichsen MM, Løvås K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, Fougner KJ, Berg TJ, Bollerslev J, Mella B, Carlson JA, Erlich H, Husebye ES (2009). "Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry". J. Clin. Endocrinol. Metab. 94 (12): 4882–90. doi:10.1210/jc.2009-1368. PMID 19858318.
  2. Betterle C, Morlin L (2011). "Autoimmune Addison's disease". Endocr Dev. 20: 161–72. doi:10.1159/000321239. PMID 21164269.
  3. Eisenbarth GS, Gottlieb PA (2004). "Autoimmune polyendocrine syndromes". N. Engl. J. Med. 350 (20): 2068–79. doi:10.1056/NEJMra030158. PMID 15141045.
  4. Badenhoop K, Walfish PG, Rau H, Fischer S, Nicolay A, Bogner U, Schleusener H, Usadel KH (1995). "Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease". J. Clin. Endocrinol. Metab. 80 (7): 2112–7. doi:10.1210/jcem.80.7.7608264. PMID 7608264.
  5. Corazza GR, Di Sario A, Cecchetti L, Jorizzo RA, Di Stefano M, Minguzzi L, Brusco G, Bernardi M, Gasbarrini G (1996). "Influence of pattern of clinical presentation and of gluten-free diet on bone mass and metabolism in adult coeliac disease". Bone. 18 (6): 525–30. PMID 8805992.
  6. Hoffenberg EJ, Bao F, Eisenbarth GS, Uhlhorn C, Haas JE, Sokol RJ, Rewers M (2000). "Transglutaminase antibodies in children with a genetic risk for celiac disease". J. Pediatr. 137 (3): 356–60. doi:10.1067/mpd.2000.107582. PMID 10969260.

Template:WH Template:WS